Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro Holdings, Inc (ABP)
NASDAQ:AMEX Investor Relations:
abpro.com/contact
Company Research
Source: GlobeNewswire
BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements. “We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum,” said Miles Suk, Chief Executive Officer and Chairman of Abpro. “We’ve taken decisive steps to position the Company for sustainable growth. With a leaner structure, access to flexible capital, and continued development support for our lead candidate ABP-102 from our partner Celltrion, we are now focused on execution, delivering results for our shareholders and meaningful impact for patients.” In addition to the reverse stock split whic
Show less
Read more
Impact Snapshot
Event Time:
ABP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABP alerts
High impacting Abpro Holdings, Inc news events
Weekly update
A roundup of the hottest topics
ABP
News
- Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]Yahoo! Finance
- Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive CancersGlobeNewswire
- Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Abpro (NASDAQ:ABP) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to aMarketBeat
- Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell EngagerGlobeNewswire
ABP
Sec Filings
- 12/15/25 - Form 8-K
- 12/9/25 - Form 8-K
- 12/3/25 - Form EFFECT
- ABP's page on the SEC website